Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633485 | 0.88 | EHMT2 (0.35) | EHMT2EHMT1CCNT1ESR1 | |
| SCHEMBL15833953 | 0.87 | EHMT2 (0.35) | EHMT2EHMT1CCNT1ESR1 | |
| SCHEMBL19633400 | 0.86 | EHMT2 (0.36) | EHMT2EHMT1MTORESR1 | |
| SCHEMBL15834819 | 0.86 | EHMT2 (0.40) | EHMT2EHMT1MTORKCNQ3KCNQ2 | |
| SCHEMBL17300774 | 0.83 | EHMT2 (0.38) | EHMT2EHMT1MTORKCNQ3KCNQ2 | |
| SCHEMBL19957555 | 0.82 | CCNT1 (0.33) | CCNT1ESR1 | |
| SCHEMBL23304427 | 0.81 | NAPEPLD (0.39) | EHMT2EHMT1MTORKCNQ3KCNQ2 | |
| SCHEMBL23304386 | 0.81 | PIK3CA (0.40) | EHMT2EHMT1MTORKCNQ3KCNQ2 | |
| SCHEMBL25063004 | 0.78 | NAPEPLD (0.40) | EHMT2EHMT1KCNQ3KCNQ2 | |
| SCHEMBL15834078 | 0.75 | RXRA (0.32) | CCNT1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | EHMT2 24/4885EHMT1 20/4885MTOR 445/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | EHMT2 24/4885EHMT1 20/4885MTOR 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.